DLST Antibody (C-term) Blocking Peptide

Background:
DLST catalyzes the overall conversion of 2-oxoglutarate to succinyl-CoA and CO2. It contains multiple copies of 3 enzymatic components: 2-oxoglutarate dehydrogenase (E1), dihydrolipoamide succinyltransferase (E2) and lipoamide dehydrogenase (E3).

Other Names:
Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial, 2-oxoglutarate dehydrogenase complex component E2, OGDC-E2, Dihydrolipoamide succinyltransferase component of 2-oxoglutarate dehydrogenase complex, E2K, DLST, DLTS

Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP2899b was selected from the C-term region of human DLST. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Gene Name: DLST (HGNC:2911)

Gene ID: 1743
Primary Accession: P36957
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.